Abstract
Somatostatin receptor targeting of neuroendocrine tumors using radiolabeled somatostatin agonists is today an established method to image and treat cancer patients. However, in a study using an animal tumor model, somatostatin receptor antagonists were shown to label sst2- and sst3-expressing tumors in vivo better than agonists, with comparable affinity even though they are not internalized into the tumor cell. In the present study, we evaluated the in vitro binding of the antagonist 177Lu-DOTA-pNO2-Phe-c (dCys-Tyr-dTrp-Lys-Thr-Cys) dTyrNH2 (177Lu-DOTA-BASS) or the 177Lu-DOTATATE agonist to sst2-expressing human tumor samples. Methods: Forty-eight sst2-positive human tumor tissue samples (9 ileal carcinoids, 10 pheochromocytomas, 7 breast carcinomas, 10 renal cell carcinomas, and 12 non-Hodgkin lymphomas) were analyzed by in vitro receptor autoradiography for the expression of sst2, comparing the binding capacity of 177Lu-DOTA-BASS and 177Lu-DOTATATE in successive tissue sections. The autoradiograms were quantitated using an electronic autoradiography detection system. Results: In all cases, the radiolabeled antagonist bound to more receptor sites than did the agonist. The mean ratios of the antagonist 177Lu-DOTA-BASS to the agonist 177Lu-DOTATATE were 4.2 ± 0.5 in the 9 ileal carcinoids, 12 ± 3 in the 10 pheochromocytomas, 11 ± 4 in the 7 breast carcinomas, 5.1 ± 0.6 in the 10 renal cell carcinomas, and 4.8 ± 0.7 in the 12 non-Hodgkin lymphomas. Conclusion: The present in vitro human data, together with previous in vivo animal tumor data, are strong arguments indicating that sst2 antagonists may be worth testing in vivo in patients in a wide range of tumors including nonneuroendocrine tumors.
In the last few years, peptide hormone receptors have become increasingly attractive for diagnostic imaging and peptide-receptor radionuclide therapy because of their overexpression in certain human tumors (1–3). In particular, somatostatin receptor tumor targeting currently constitutes a well-established method to image or to treat patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. 111In-pentetreotide (OctreoScan; Covidien), for instance, has been widely used to visualize these types of tumors (4,5). Furthermore, in clinical studies, somatostatin receptor radionuclide therapy with patients with neuroendocrine tumors has given promising results (6). Indeed, several excellent somatostatin agonists, among which are 90Y-DOTATOC and 177Lu-DOTATATE, have been developed in the last few years and are now routinely used in the clinic to treat patients with neuroendocrine tumors (7,8). An important feature of such agonist radioligands is that after binding to the receptor, they have to be internalized into the tumor cell by receptor-mediated endocytosis, leading to an accumulation of the radioactive agonist within the tumor cell (9,10). Interestingly, it has recently been shown for sst2 and sst3 in an animal tumor model that somatostatin antagonists with high affinity for the receptor can also have excellent properties for peptide receptor targeting (11). Despite the fact that there is a minimal internalization of the receptor–antagonist complex into tumor cells, the antagonist readily labels somatostatin receptor–expressing tumors at least as well as, and often even better than, agonists and has, moreover, a higher tumor uptake than the corresponding agonist, with comparable affinity. A reason for this observation may be that antagonists bind to a larger population of binding sites and have a lower dissociation rate than agonists (11). Confirming data were obtained with another peptide hormone receptor, the gastrin-releasing peptide receptor (12); this study showed, in comparative in vitro–in vivo experiments, the superiority of the antagonist demobesin 1 as a tumor-targeting agent to the comparable potent agonist demobesin 4. The aim of the present study was to evaluate the in vitro binding behavior of the antagonist 177Lu-DOTA-BASS, compared with the established agonist radioligand 177Lu-DOTATATE, on several different, well-characterized human tumor samples by in vitro receptor autoradiography.
MATERIALS AND METHODS
Reagents
All reagents were of the best grade available and were purchased from common suppliers. DOTA-pNO2-Phe-c (dCys-Tyr-dTrp-Lys-Thr-Cys) dTyrNH2 (DOTA-BASS) and somatostatin-28 (SRIF-28) were provided by Jean E. Rivier (The Salk Institute), and DOTATATE was provided by Helmut R. Mäcke (Basel, Switzerland).
Tissues
Fresh-frozen tissue samples from surgically resected tumors, which were characterized for their sst2 expression in previous studies (13–17), were used. The study conformed to the ethical guidelines of the Institute of Pathology of the University and the University Hospital of Berne and was reviewed by the Institutional Review Board.
Preparation of Radiotracer 177Lu-DOTA-BASS and 177Lu-DOTATATE
177Lu-DOTA-BASS and 177Lu-DOTATATE were prepared after incubation of 5.5–6.5 nmol of each conjugate with 185–222 MBq of 177LuCl3 at 95°C for 30 min in 0.5 mL of sodium acetate buffer (0.4 M, pH 5.0). Quality control was performed by reversed-phase high-performance liquid chromatography as previously described (18). The radiotracer solutions were prepared by dilution with ascorbic acid solution (50 mg/mL, pH 5.0), in a radioactivity concentration of 37 MBq/mL (specific activity, 40 MBq/nmol).
Binding Affinities Determined by Receptor Autoradiography Using [Leu8, d-Trp22, 125I-Tyr25]-SRIF-28 (125I-LTT-SRIF-28)
Cell membrane pellets were prepared as previously described and stored at −80°C (19). Receptor autoradiography was performed on 20-μm-thick cryostat (HM 500; Microm) sections of the membrane pellets, mounted on microscope slides, and then stored at −20°C as previously described (19,20). For each of the tested compounds, complete displacement experiments with the universal SRIF radioligand 125I-LTT-SRIF-28 (74,000 GBq/mmol [2,000 Ci/mmol]; Anawa) using 15,000 cpm/100 μL and increasing concentrations of the unlabeled peptide ranging from 0.1 to 1,000 nM were performed. As a control, unlabeled SRIF-28 was run in parallel, using the same increasing concentrations. The sections were incubated with 125I-LTT-SRIF-28 for 2 h at room temperature in Tris-HCl buffer (170 mmol/L; pH 8.2), containing 1% bovine serum albumin (BSA), bacitracin (40 mg/L), and MgCl2 (10 mmol/L) to inhibit endogenous proteases. The incubated sections were washed twice for 5 min in cold Tris-HCl (170 mmol/L; pH 8.2) containing 0.25% BSA. After a brief dip in Tris-HCl (170 mmol/L; pH 8.2), the sections were dried quickly and exposed for 1 wk to BioMax MR film (Kodak). Fifty percent inhibitory concentration values were calculated after quantification of the data using a computer-assisted image processing system as described previously (21). Tissue standards (autoradiographic 125I or 14C microscales; GE Healthcare) that contain known amounts of isotope, cross-calibrated to tissue-equivalent ligand concentrations, were used for quantification (20,22).
In Vitro Receptor Autoradiography of Cancer Tissues with 177Lu-Labeled Analogs
For in vitro somatostatin receptor autoradiography using 177Lu-labeled analogs, 20-μm-thick cryostat (HM 500; Microm) sections of fresh-frozen tissue samples were mounted on microscope slides and then stored at −20°C as previously described (19,20). The sections were incubated with 177Lu-DOTATATE or 177Lu-DOTA-BASS using 20,000 cpm/100 μL for 2 h at room temperature in Tris-HCl buffer (170 mmol/L; pH 8.2), containing 1% BSA, bacitracin (40 mg/L), and MgCl2 (10 mmol/L) to inhibit endogenous proteases. The incubated sections were washed twice for 5 min in cold Tris-HCl (170 mmol/L; pH 8.2) containing 0.25% BSA. Afterward, they were completely immersed for 10 s in Tris-HCl (170 mmol/L; pH 8.2) and then quickly dried. To determine the nonspecific binding of the 177Lu-labeled compounds, unlabeled DOTATATE or DOTA-BASS at a concentration of 100 nM was added to the radioactive samples and run in parallel. Radioactivity bound to the sections was quantitated immediately by electronic autoradiography (23). The electronic autoradiography detection system (InstantImager 2024; Packard Instruments) allowed a direct measurement of the radioactivity. The radioactive decays of the samples were measured for 60 min, and the counts per area were determined using the InstantImager quantitation software. The data obtained with the InstantImager were further validated using the following 2 different established methods: by exposition of the sections to BioMax MR film (Kodak) for 6, 17, or 66 h (depending on the receptor density on the tumor tissue), with subsequent quantification of the data for the determination of the binding affinities; and by counting the tissues for 1 min in a γ-counter (Wizard 1470 automatic γ-counter; PerkinElmer) after having carefully scraped the tissue material from the slide and transferred it into a counting vial. The 2 validation methods were found to give results comparable to those obtained with the InstantImager (not shown).
Electronic Autoradiography
The InstantImager 2024 consists of a multiwire proportional chamber, filled with counting gas (argon, 96.5%; CO2, 2.5%; and isobutane, 1%), and a microchannel array detector. β-particles or secondary electrons from γ-radiation cause gas ionization in one of 214,420 microchannels of 0.4-mm diameter. The voltage potential in the channel causes an electron avalanche detected in the anode–cathode wire planes above. A fast digital processor calculates the position on the sample plate (20 × 24 cm), and software running on a standard personal computer is used for tasks such as image acquisition and display. The online detection provides a direct quantitation of radioactivity in 2-dimensional samples. The electronic autoradiography system has been shown to be suitable for the use of most of the common radioisotopes used in nuclear medicine such as 67Ga, 99mTc, 111In, 123I, 125I, and 131I (23). We have used the InstantImager to quantitate tissue cryosections from autoradiography experiments treated with compounds labeled with the β- and γ-emitter 177Lu. The data obtained by electronic autoradiography were validated by 2 additional methods (radiographic film and γ-counting), giving comparable results.
RESULTS
Table 1 summarizes the sst1–sst5 affinity binding profile of the agonist DOTATATE and the antagonist DOTA-BASS obtained by in vitro receptor autoradiography using membrane pellet sections of transfected cells stably expressing the 5 somatostatin receptors. For comparison, the values of the natural SRIF-28 are shown as reference. Both compounds, DOTATATE and DOTA-BASS, exhibit a high selectivity for sst2, and the 50% inhibitory concentration for sst2 is in the low nanomolar range and was identical for both compounds, a prerequisite to compare them directly in autoradiography binding experiments.
sst1–sst5 Affinity Profile of 2 Somatostatin Analogs, Compared with SRIF-28 as Reference
The radioligands 177Lu-DOTA-BASS and 177Lu-DOTATATE were furthermore evaluated for their ability to bind to sst2-expressing tumor samples. To this end, receptor autoradiography was performed using 48 sst2-positive human tumor tissue samples (ileal carcinoid, pheochromocytoma, breast carcinoma, renal cell carcinoma, and non-Hodgkin lymphoma). Autoradiograms of representative examples for all 5 tumor types analyzed are shown in Figure 1. Both radioligands efficiently bind to the sst2 receptor on the different tumor tissues (“total” column in Fig. 1), and competitive binding of the radioligands is observed after the addition of unlabeled DOTATATE and DOTA-BASS, respectively (“NS” column in Fig. 1). In all cases, the sst2-expressing tumors were more intensely labeled in vitro with the antagonist 177Lu-DOTA-BASS than with the agonist 177Lu-DOTATATE. To obtain quantitative data, the autoradiography experiments were analyzed using the InstantImager as the electronic autoradiography detection system (23). Figure 2 shows bar graphs with the quantitation of the autoradiography experiments of the 5 different tumor types. The data illustrate the superiority of the antagonist 177Lu-DOTA-BASS over the agonist 177Lu-DOTATATE in respect to binding to the 5 tumor tissue types. The mean ratios of 177Lu-DOTA-BASS to 177Lu-DOTATATE were 4.2 ± 0.5 in 9 ileal carcinoids, 12 ± 3 in 10 pheochromocytomas, 11 ± 4 in 7 breast carcinomas, 5.1 ± 0.6 in 10 renal cell carcinomas, and 4.8 ± 0.7 in 12 non-Hodgkin lymphomas. Additionally, the results obtained with the InstantImager were confirmed by 2 alternative detection methods: the autoradiography experiments were quantitated either by exposing the slides for an adequate time on radiographic films and determining the relative optical densities, or by transferring the labeled tissue from the slides to counting vials and measuring the cpm in a γ-counter (not shown).
Comparison of 177Lu-DOTATATE and 177Lu-DOTA-BASS receptor autoradiographic binding in successive sections of various types of human cancers (ileal carcinoid, pheochromocytoma, breast carcinoma, renal cell carcinoma, and non-Hodgkin lymphoma) expressing sst2. Columns from left to right represent hematoxylin and eosin staining, total and nonspecific binding of 177Lu-DOTATATE, and total and nonspecific binding of 177Lu-DOTA-BASS. Binding is markedly stronger with antagonist 177Lu-DOTA-BASS. HE = hematoxylin and eosin; NHL = non-Hodgkin lymphoma; NS = nonspecific; Pheo = pheochromocytoma; RCC = renal cell carcinoma.
Quantitation of in vitro receptor autoradiography experiments with various types of human cancers (ileal carcinoid, pheochromocytoma, breast carcinoma, renal cell carcinoma, and non-Hodgkin lymphoma) using 177Lu-DOTATATE and 177Lu-DOTA-BASS as radioligands. Shown are bar graphs of specific binding (counts/h) of radioligands to tumor sections after quantitation using InstantImager. For all tested human tumor types, antagonist 177Lu-DOTA-BASS exhibited markedly better binding behavior. NHL = non-Hodgkin lymphoma; Pheo = pheochromocytoma; RCC = renal cell carcinoma; Spec. = specific.
DISCUSSION
This in vitro study on human tumor tissues shows that antagonist radioligands bind to more sst2 receptors in tumor cells than agonist radioligands. It therefore complements a previous study performed in vivo in animal tumor models bearing sst2- or sst3-expressing tumors. In that study, Ginj et al. showed that radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor tumor targeting, leading to a change of paradigm in nuclear medicine (11).
We show here that the observation of more binding sites detected with antagonist radioligands can be made with a large variety of different tumor types. This observation can be made in the classic somatostatin receptor–expressing tumor targets such as ileal carcinoids, which can readily be targeted successfully in patients with agonist tracers (6). Our in vitro study suggests that the use of sst2 antagonist radioligands such as 177Lu-DOTA-BASS increases tumor binding, compared with agonist binding, by 4.2 times, on average, in our 9 samples. This binding may increase the localization accuracy for tumors and metastases but also increase the efficacy of radiotherapeutic intervention with such antagonist tracers. The same observation and conclusions can be made for another type of neuroendocrine tumor, the pheochromocytoma, also often localized in patients with sst2 agonist radioligand (24); we found for this tumor an even higher increase in binding with the antagonist, namely 12.3-fold, compared with agonist.
Of particular interest are the results in the nonneuroendocrine, nonclassic tumor targets, namely tumors that normally express a low density of receptors, such as breast carcinomas, renal cell cancers, or non-Hodgkin lymphomas (14–16,25,26). Those tumors are not currently among those being routinely investigated with 111In-pentetreotide imaging. It is therefore impressive to see that by using the antagonist radioligand, it is possible to increase in vitro the number of binding sites in breast carcinomas and renal cell cancers 11.4- and 5.1-fold, respectively. Breast carcinomas and renal cell cancers reach, under such conditions, a receptor level much above (breast carcinomas) or almost equal to (renal cell cancers) the number of receptors detected in pheochromocytomas with the agonist radioligand. Our data therefore suggest that, using antagonist radioligands, compared with agonist imaging, it may be possible to also achieve in vivo an improved uptake relative to background in breast and renal cell cancers.
Non-Hodgkin lymphomas normally expressing a low amount of sst2 showed a 4.8-fold increase in receptor number with the antagonist radioligand, reaching levels that may be detected more easily in vivo than with current agonists (14,27). Thus, it is feasible that non-Hodgkin lymphomas might be amenable to radiotherapy with therapeutically radiolabeled antagonists, because these tumors are radiosensitive; they may therefore be more successfully treated with such a strategy than are currently the neuroendocrine tumors, known as not particularly radiosensitive tumors.
Once it is confirmed in a larger cohort of patients that classic neuroendocrine tumors can be better visualized with sst2 antagonists than with sst2 agonists, as recently demonstrated in a preliminary study with 5 patients (28), we may suggest, on the basis of the present study, that the in vivo targeting of nonclassic tumors such as breast carcinomas, renal cell cancers, and non-Hodgkin-lymphomas be reevaluated.
CONCLUSION
The present in vitro human data, together with previous in vivo animal tumor data (11), are strong arguments indicating that sst2 antagonists may be worth testing in vivo in patients in a wide range of sst2-expressing tumors, also including nonneuroendocrine tumors. Such sst2 antagonist radioligands should be useful not only for diagnostic tumor imaging but also for targeted tumor radiotherapy.
Footnotes
Published online Nov. 8, 2011.
- © 2011 by Society of Nuclear Medicine
REFERENCES
- Received for publication July 14, 2011.
- Accepted for publication August 18, 2011.
Jump to section
Related Articles
Cited By...
- The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?
- First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
- Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan
- Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
- Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists
- SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- Citius, Altius, Fortius: An Olympian Dream for Theranostics
- Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
- The Somatostatin Analog 188Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
- Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications